AI-generated analysis. Always verify with the original filing.
Kezar Life Sciences, Inc. entered into an Asset Purchase Agreement dated March 6, 2026, with Enodia Therapeutics SAS, a French simplified joint stock company, completing the acquisition or disposition of assets. The agreement is filed as Exhibit 2.1.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 6, 2026, Kezar Life Sciences, Inc. (the “Company”) and Enodia Therapeutics SAS, a French simplified joint s
Completion of Acquisition or Disposition of Assets. The information contained above in Item 1.01 is hereby incorporated by reference into this Item 2.01. Item 7
in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 2.1* Asset Purchase Agreement, dated as of March 6, 2026, between Enodia Therapeutics SA
Acquisition / Disposition
Material Agreement